Pleural Dynamics Announces Completion of Enrollment of “The ACES Study for Aseptic Pleural Effusions,” a Post Market Study Evaluating the Novel ACES Automatic Continuous Effusion Shunt System Pleural ...
The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...
MINNEAPOLIS--(BUSINESS WIRE)--Pleural Dynamics, a medical device company that is building solutions for recurrent fluid collections in the body, announced today that the final patient in “The ACES™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback